Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 2:35 p.m. ET.
波士顿，2024年11月26日（环球新闻社）—Aura Biosciences，Inc.（纳斯达克：AURA），一家临床阶段的生物技术公司，正在开发用于保留器官功能的固体肿瘤精准疗法，今天宣布Elisabet de los Pinos博士，首席执行官，将于2024年12月3日星期二下午2:35在第7届Evercore ISI HealthCONx大会上参加炉边谈话。
The live webcast of the fireside chat will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company's website at , where a replay of the webcast will be archived for 90 days following the presentation date.
炉边谈话的现场网络直播将在公司网站的“投资者与媒体”页面的“事件与演示文稿”部分上提供，网站上将存档网络直播的重播，持续90天直到演示日期结束。
About Aura Biosciences
关于Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. Aura Biosciences is headquartered in Boston, MA. Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.
Aura生物科学是一家临床阶段的生物技术公司，专注于开发用于保护器官功能的固体肿瘤精准疗法。我们的首席候选药物bel-sar（AU-011）目前在初级脉络膜黑色素瘤的后期开发阶段，并在其他眼科肿瘤适应症和膀胱癌的早期开发阶段。Aura生物科学总部位于马萨诸塞州波士顿。我们的使命是成长为一家创新的全球肿瘤公司，积极改善患者的生活。
For more information, visit aurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.
欲了解更多信息，请访问aurabiosciences.com。您可以在X（以前叫做Twitter） @AuraBiosciences上关注我们，并在LinkedIn上访问我们的主页。
Investor Contact:
Alex Dasalla
Head of Investor Relations and Corporate Communications
IR@aurabiosciences.com
投资者联系人：
Alex Dasalla
投资者关系和企业沟通主管
IR@aurabiosciences.com
Media Contact:
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744
媒体联系：
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744
